Balanced news tone
News Sentiment
FENC sentiment intelligence
Fennec Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
48 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+0.1% over one week, +15.9% over four weeks, trend active, and materially above fair value.
Understanding the Setup: (FENC) and Scalable Risk
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
76/100 classification
One-week reaction
0.1%
Price digesting
Trend fit
Trend active
15.9% over four weeks
Fair value
37.0%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
8
Neutral
35
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Stock Traders Daily
Direct company coverage
Understanding the Setup: (FENC) and Scalable Risk
This article analyzes Fennec Pharmaceuticals Inc. (FENC), highlighting conflicting sentiment across different time horizons despite a breakout underway that suggests higher levels. It details AI-generated trading strategies including position, momentum breakout, and risk hedging,
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 13 Jul 2026 16:40
- Source
- Stock Traders Daily
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Fennec (NASDAQ: FENC) ex-director exercises options, sells shares for taxes
Fennec Pharmaceuticals Inc.'s former director, Rosty Raykov, exercised stock options for 15,597 shares and received 2,778 restricted shares. Concurrently, he sold 9,599 shares at $10.41 each to cover tax obligations. These transactions were executed on July 1, 2026, under a pre-a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 19:42
- Source
- Stock Titan
Investing.com India
Direct company coverage
Form 144 FENNEC PHARMACEUTICALS INC. For: 1 July By Investing.com
This article announces a Form 144 filing for FENNEC PHARMACEUTICALS INC. for July 1st, as reported by Investing.com. It also includes a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility of markets and th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 03:10
- Source
- Investing.com India
Stock Titan
Direct company coverage
FENNEC (FENC) CFO Andrade gains 1,703 vested shares, now holds 290,972
FENNEC PHARMACEUTICALS INC. CFO Robert Andrade acquired 1,703 common shares through a grant/award acquisition at a price of $0.00 per share. These shares were released from restrictions on prior awards from May 16, 2024, and March 28, 2025. Following this transaction, Andrade dir
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award
Fennec Pharmaceuticals Inc.'s Chief Strategy Officer, Christiana Marie Cioffi, received a grant of 156 common shares at no cost, which increased her direct holdings to 24,332 shares. This transaction represents the release of restrictions on stock previously awarded on March 28,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Fennec Pharmaceuticals (FENC) CCO receives 168-share award, holds 21,183
Fennec Pharmaceuticals Chief Commercial Officer Terry L. Evans was awarded 168 common shares as part of an equity compensation plan, increasing his total direct holdings to 21,183 common shares. This transaction was not an open-market purchase but rather the release of restricted
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Fennec Pharmaceuticals (NASDAQ: FENC) CEO reports 1,159-share award release
Fennec Pharmaceuticals CEO Jeffrey S. Hackman reported the acquisition of 1,159 common shares on June 30, 2026. These shares were released from restrictions related to an award granted on March 28, 2025, and involve no purchase price, signaling a routine equity award release rath
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
FENC (NASDAQ: FENC) plans 9,599-share option sale; prior small sales listed
A Rule 144 SEC filing indicates that FENNC PHARMACEUTICALS INC. (NASDAQ: FENC) has a proposed sale of 9,599 common shares tied to a stock option exercise planned for July 1, 2026. The filing also lists prior dispositions by Rostislav Raykov, including 9,747 shares sold on June 1,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Fennec (NASDAQ: FENC) CMO awarded 168 shares, holds 21,183
Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, reported the acquisition of 168 common shares as a compensation-related grant, with a price of $0.00 per share. These shares were released from restrictions from an award originally granted in March 2025. Followi
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 2500 Value Benchmark
Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and Small Cap Comp Value Benchmarks. The company, a commercial-s
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 29 Jun 2026 11:41
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Fennec Pharmaceuticals Inc. – NASDAQ:FENC
The article briefly presents financial data for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), specifically its enterprise value to EBITDA forward metric. It appears to be a stub or data point from a financial platform like TradingView, with no further analytical content provided be
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 18:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Fennec Pharmaceuticals Inc. – FWB:RV41
This article provides forward-looking enterprise value to EBIT data for Fennec Pharmaceuticals Inc. (FWB:RV41) on the Frankfurt Stock Exchange. It highlights the availability of financial information and market data for the company on the TradingView platform.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 10:39
- Source
- TradingView
marketscreener.com
Direct company coverage
Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell Small Cap Comp Value Benchmark
Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell Small Cap Comp Value Benchmark, as well as multiple other Russell benchmarks including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and 2500 Value benchmarks on June 28-29, 2026. The
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 26 Jun 2026 17:39
- Source
- marketscreener.com
The Globe and Mail
Direct company coverage
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Pharmaceuticals Inc. announced the grant of incentive stock option awards to a new non-executive employee to purchase 15,000 common shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are inducements for the employee's new employment. The stock options have an
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 26 Jun 2026 15:09
- Source
- The Globe and Mail
TradingView
Direct company coverage
Price to earnings forward of Fennec Pharmaceuticals Inc. – NASDAQ:FENC
This article provides a brief snapshot of the "Price to earnings forward" for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) from TradingView. The content is primarily a data placeholder, indicating the stock's financial overview and market information without detailed figures. It al
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 13:39
- Source
- TradingView
TradingView
Direct company coverage
Fennec Pharmaceuticals Inc. Actuals & Estimates (TSX:FRX)
This article provides an overview of Fennec Pharmaceuticals Inc. (TSX:FRX), offering details on its current stock price, historical performance, analyst forecasts, and financial data. It covers aspects like market capitalization, volatility, earnings, revenue, and employee count,
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 11:41
- Source
- TradingView
TradingView
Direct company coverage
FENC Forecast — Price Target — Prediction for 2027
Fennec Pharmaceuticals Inc. (FENC) has a 1-year price target of $15.67 from 6 analysts, with a current stock price of $11.02. The stock has seen significant increases over the past week, month, and year. Analysts provide a future price forecast with a maximum estimate of $18.00 a
- Tone
- Positive 71/100
- Event
- Guidance
- Published
- 26 Jun 2026 09:41
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Fennec Pharmaceuticals Inc. – NASDAQ:FENC
This article displays the "Price to sales forward" financial metric for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) on TradingView. It shows the value of this metric over a specific period, along with its change and percentage change. The content also includes navigational and pla
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 05:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Fennec Pharmaceuticals Inc. – BOATS:FENC
This article provides the "Price to earnings forward" metric for Fennec Pharmaceuticals Inc. (BOATS:FENC) as available on TradingView. It highlights that the market was closed at the time of viewing, showing no trades. The core content is a single data point within a financial pl
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:39
- Source
- TradingView
TradingView
Direct company coverage
Fennec Pharmaceuticals Inc. Actuals & Estimates (LS:A12A5F)
Fennec Pharmaceuticals Inc. (A12A5F) stock is currently trading at 8.7500 EUR, showing an 8.02% increase in the past 24 hours, with analysts forecasting a price range between 11.27 EUR and 15.60 EUR. The company will release its next earnings report on August 6, 2026, and reporte
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:11
- Source
- TradingView
TradingView
Direct company coverage
Fennec Pharmaceuticals Inc. Actuals & Estimates (BOATS:FENC)
This article provides financial actuals and estimates for Fennec Pharmaceuticals Inc. (FENC), including income statement, balance sheet, and cash flow data, alongside analyst price targets and historical performance. It details recent earnings, revenue figures, and upcoming earni
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 25 Jun 2026 21:39
- Source
- TradingView
TradingView
Direct company coverage
A12A5F Forecast — Price Target — Prediction for 2027
This article provides a forecast for Fennec Pharmaceuticals Inc. (A12A5F) stock, including analyst price targets and future predictions. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report. The piece also pr
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 16:11
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Fennec Pharmaceuticals Inc. – BOATS:FENC
This article provides the "Price to book forward" financial metric for Fennec Pharmaceuticals Inc. (BOATS:FENC). It indicates that the company's market is currently closed with no trades. The information is presented within the context of TradingView's financial data and tools.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 16:11
- Source
- TradingView
Stock Traders Daily
Direct company coverage
Precision Trading with Fennec Pharmaceuticals Inc. (FENC) Risk Zones
This article analyzes Fennec Pharmaceuticals Inc. (FENC) providing AI-generated trading strategies and risk zones. Key findings include divergent sentiment indicating choppiness, a resistance test, and an exceptional risk-reward short setup. It offers specific entry, target, and
- Tone
- Negative 35/100
- Event
- Analyst action
- Published
- 22 Jun 2026 14:10
- Source
- Stock Traders Daily
Stock Titan
Direct company coverage
Fennec awards new employee 15,000 stock options at $9.06
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
TradingKey
Direct company coverage
Fennec Pharmaceuticals Inc (FENC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Fennec Pharmaceuticals Inc (FENC), highlighting its current earnings forecast score of 8.33 and ranking within the Pharmaceuticals industry. Analysts have set an average price target of $14.00 for FENC, with a consensus "Buy" rating
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jun 2026 18:40
- Source
- TradingKey
TradingKey
Direct company coverage
Fennec Pharmaceuticals Inc (FENC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fennec Pharmaceuticals Inc's (FENC) dividend and stock split history. It indicates that FENC has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock pricing information
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 09:41
- Source
- TradingKey
TradingKey
Direct company coverage
Fennec Pharmaceuticals Inc (FENC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Fennec Pharmaceuticals Inc (FENC), highlighting its current price momentum score of 6.84 and its trading range between resistance at 10.17 and support at 8.23. The analysis includes a summary of various technical indicators, such as M
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 17 Jun 2026 07:02
- Source
- TradingKey